Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2011 Dec;68(6):1595-602.
doi: 10.1007/s00280-011-1657-1. Epub 2011 May 10.

A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: Southwest Oncology Group study S0202

Syma Iqbal  1 , Cathryn Rankin, Heinz-Josef Lenz, Philip J Gold, Syed A Ahmad, Anthony B El-Khoueiry, Michael J Messino, Randall F Holcombe, Charles D Blanke
Affiliations
Clinical Trial

A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: Southwest Oncology Group study S0202

Syma Iqbal et al. Cancer Chemother Pharmacol. 2011 Dec.

Abstract

Purpose: Patients with gallbladder cancer or cholangiocarcinoma were treated with the combination of gemcitabine 1,000 mg/m(2) IV over 100 min on days 1 and 8 and capecitabine 650 mg/m(2) BID PO on days 1-14, administered every 21 days.

Methods: The primary objective of this study was to assess the response rate (confirmed complete and partial responses) of gemcitabine and capecitabine used in advanced/metastatic biliary neoplasms. Secondary objectives included overall survival and toxicities.

Results: The study accrued 57 patients from September 2003 to April 2005. Three patients were ineligible, and two others received no treatment. Characteristics of analyzable patients: 35 (67%) cholangiocarcinoma, 17 (33%) gallbladder cancer; PS 0 (18 pts), 1 (26 pts), 2 (8 pts); 26 (50%) men; median age 58.8 years (29.5-85.6). Among 51 patients evaluated for toxicity, 6 experienced grade 4 toxicities. Among 52 patients, there were 7 confirmed partial responses for a confirmed response probability of 13% (95% CI: 6-26%). Six patients had an unconfirmed partial response for an overall response probability of 25% (95% CI: 14-39%). Twelve patients (23%) demonstrated stable disease. The 6-month overall survival was 55% (95% CI: 41-69%), and median survival was 7 months (95% CI: 5-8 months).

Conclusions: The combination of gemcitabine and capecitabine is a well-tolerated regimen with activity in patients with advanced gallbladder cancer and cholangiocarcinoma.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Kaplan-Meier Curve for overall survival in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma treated with gemcitabine and capecitabine
Figure 2
Figure 2
Overall survival by TS5 status in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma treated with gemcitabine and capecitabine
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Cancer Facts & Figures. Atlanta, GA: American Cancer Society, Inc; 2008.
    1. Serra I, Calvo A, Baez S, et al. Risk factors for gallbladder cancer.An international collaborative case-control study. Cancer. 1996;78:1515–7. - PubMed
    1. Falkson G, MacIntyre JM, Moertel CG. Eastern Cooperative Oncology Group experience with chemotherapy for inoperable gallbladder and bile duct cancer. Cancer. 1984;54:965–9. - PubMed
    1. Takada T, Kato H, Matsushiro T, et al. Prospective randomized trial comparing 1/2 FAM (5-fluorouracil (5-FU) + adriamycin + mitomycin C) versus palliative therapy for the treatment of unresectable pancreatic and biliary tract carcinomas (the 2nd trial in non-resectable patients) Japanese Study Group of Surgical Adjuvant Therapy for Carcinomas of the Pancreas and Biliary Tract Gan To Kagaku Ryoho. 1996;23:707–14. - PubMed
    1. Kajanti M, Pyrhonen S. Epirubicin-sequential methotrexate-5-fluorouracil-leucovorin treatment in advanced cancer of the extrahepatic biliary system. A phase II study. Am J Clin Oncol. 1994;17:223–6. - PubMed

Publication types

MeSH terms

Grants and funding